Leuprorelin is a synthetic peptide analog of gonadotropin-releasing hormone (GnRH) and is used in the treatment of various conditions such as prostate cancer, endometriosis, and uterine fibroids. However, during the manufacturing process, impurities may be introduced which can affect the quality, safety, and efficacy of the drug. These impurities may include related compounds, degradation products, and residual solvents, among others. Therefore, it is important to monitor and control the levels of leuprorelin impurities to ensure that the drug is of high quality and suitable for use in patients.
